Coultreon banks $125M to support testing of former Galapagos immune drug
Source: BioPharma Dive - Latest News
Backed by Novo Holdings, Regeneron’s venture arm and several others, the biotech believes an oral drug licensed from Galapagos might hold potential treating many immunological diseases.